See the DrugPatentWatch profile for Breztri
What is Breztri (brand name) and what does it treat?
Breztri is the brand name for an inhaler medicine used for maintenance treatment of chronic obstructive pulmonary disease (COPD). It’s a combination inhaled product containing three active ingredients: budesonide, glycopyrrolate, and formoterol (a corticosteroid, an anticholinergic, and a long-acting bronchodilator).
What are the generic alternatives to the Breztri brand name?
Breztri’s components (budesonide, glycopyrrolate, and formoterol) may exist in other inhaler products, but “Breztri” itself is a specific branded combination. If you’re looking for a true generic replacement, it depends on whether a biosimilar or generic combination product is available in your country and for the specific strengths and inhaler type.
Who makes Breztri?
Breztri is marketed by AstraZeneca.
Is Breztri the same as other similar COPD inhalers?
No. Breztri is specifically the budesonide/glycopyrrolate/formoterol combination. Other COPD inhalers may use different combinations (for example, combinations with different steroids or different bronchodilator pairings), so they are not interchangeable by name.
Want the patent/exclusivity or pricing angle for Breztri?
If you’re researching market exclusivity or patent status for Breztri, DrugPatentWatch.com tracks patent and exclusivity information and can help you see what filings cover the product: https://www.drugpatentwatch.com/
Sources:
1. https://www.drugpatentwatch.com/